HLS TherapeuticsTSX:HLS -1.12%62 Days Payable is 347.55 as of Mar. 2026, which is 49% below its 10-year median of 682.45. GuruFocus rates TSX:HLS with a GF Score™ of 62/100 and a GF Value™ of C$4.46 (Fairly Valued). The stock has 4 warning signs investors should review. Among 923 Drug Manufacturers companies, HLS Therapeutics ranks better than 91.77% on this metric.
The historical rank and industry rank for HLS Therapeutics's Days Payable or its related term are showing as below:
TSX:HLS'
s Days Payable Range Over the Past 10 Years
Min: 85.46 Med: 682.45 Max: 2467.77
Current: 340.58
During the past 13 years, HLS Therapeutics's highest Days Payable was 2467.77. The lowest was 85.46. And the median was 682.45.
TSX:HLS's Days Payable is ranked better than 91.77% of 923
companies
in the Drug Manufacturers industry
Industry Median: 90.98
vs TSX:HLS: 340.58
HLS Therapeutics's Days Payable
increased
from Mar. 2025 (329.59) to Mar. 2026 (347.55).
It may suggest that HLS Therapeuticsdelayed paying its suppliers.
HLS Therapeutics Days Payable Related Terms
HLS Therapeutics Days Payable Historical Data
* Premium members only.
The historical data trend for HLS Therapeutics's Days Payable can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, HLS Therapeutics's Days Payable, along with its competitors' market caps and Days Payable data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
HLS Therapeutics Days Payable vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, HLS Therapeutics's Days Payable distribution charts can be found below:
* The bar in red indicates where HLS Therapeutics's Days Payable falls into.
Days Payable indicates the number of days that the account payable relative to cost of goods sold the company has. An increase of Days Payable may suggest that the company delays paying its suppliers.
HLS Therapeutics's Days Payable for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
HLS Therapeutics (TSX:HLS) has a Days Payable of 347.55 as of Mar. 2026. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on HLS Therapeutics and its competitors. This is 49% below median its historical median of 682.45. Over the past decade, HLS Therapeutics' Days Payable has ranged from 85.46 to 2,467.77. According to the industry distribution chart, HLS Therapeutics ranks #76 out of 923 companies in the Drug Manufacturers industry, placing it in the top 8.2%.
Is HLS Therapeutics' Days Payable too high?
HLS Therapeutics' current Days Payable of 347.55 is 49% below median its 10-year median of 682.45. Over the past 10 years, this metric has ranged from a low of 85.46 to a high of 2,467.77. The Drug Manufacturers industry median Days Payable is 90.98. HLS Therapeutics' value of 347.55 is 282% above this industry median. Based on the distribution chart, HLS Therapeutics ranks #76 out of 923 companies in the Drug Manufacturers industry, which is in the top quartile — a strong position relative to peers. Overall, HLS Therapeutics has a GF Score™ of 62/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does HLS Therapeutics' Days Payable compare to ZTS?
According to the Drug Manufacturers industry distribution chart, HLS Therapeutics ranks #76 out of 923 companies for Days Payable. This places HLS Therapeutics in the top 8% of its industry — outperforming the majority of peers. The industry median Days Payable is 90.98. HLS Therapeutics' value of 347.55 is 282% above this benchmark. Historically, HLS Therapeutics' own Days Payable has ranged from 85.46 to 2,467.77 over the past decade. While the company's 10-year median is 682.45 vs. the industry median of 90.98, HLS Therapeutics has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Days Payable for a Drug Manufacturers company?
The median Days Payable among Drug Manufacturers companies is 90.98, based on 923 companies in the industry. Companies in the top quartile (top 25%) have a Days Payable significantly above this median, while those in the bottom quartile fall well below. However, Days Payable should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. HLS Therapeutics's current Days Payable of 347.55 is 282% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Days Payable mean?
A high Days Payable can signal that a stock is expensive relative to its fundamentals. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on HLS Therapeutics and its competitors. For the Drug Manufacturers industry, the median Days Payable is 90.98 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. HLS Therapeutics's current Days Payable is 347.55, which is 49% below median its own 10-year median of 682.45. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is HLS Therapeutics stock overvalued right now?
Based on GuruFocus' analysis, HLS Therapeutics (TSX:HLS) is currently considered Fairly Valued. The stock's GF Value™ is C$4.46, compared to a current price of C$4.42 — trading 0.9% below its estimated fair value. The current Days Payable is 347.55, which is 49% below median its 10-year median of 682.45 and 282% above the Drug Manufacturers industry median of 90.98. HLS Therapeutics' overall GF Score™ is 62/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Days Payable calculated?
Days Payable is calculated from a company's financial statements. For HLS Therapeutics (TSX:HLS), the current Days Payable is 347.55 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is HLS Therapeutics (TSX:HLS) Overvalued in 2026?
Based on GuruFocus' analysis, HLS Therapeutics stock appears to be undervalued.
The current stock price of C$4.42 is trading 0.9% below its estimated GF Value™ of C$4.46.
GuruFocus considers HLS Therapeutics to be Fairly Valued.
Key valuation signals for TSX:HLS:
Days Payable: 347.55 (49% below median its 10-year median of 682.45)
GF Value™: C$4.46 vs. price of C$4.42 (0.9% below fair value)
Industry Position: 282% above the Drug Manufacturers median (#76 of 923)
No single metric tells the full story. See the TSX:HLS stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
HLS Therapeutics Inc is a specialty pharmaceutical company. It is focused on the acquisition and commercialization of branded pharmaceutical products in the North American markets. The company's products include Clozaril, Vascepa, CSAN Pronto, and others. The company earns revenue in the form of product sales and royalties, out of which product sales contribute to the majority of the revenue. The company operates in Canada, the United States, and the Rest of world, with the majority of its revenue generated from Canada.
62GF Score
Get the complete analysis for TSX:HLS
Days Payable is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
TSX:HLS has been successfully added to your 
